Papaleo Francesco, Contarino Angelo
Dipartimento di Farmacologia e Anestesiologia, Largo Meneghetti 2, 35131 Padova, Italy.
Behav Brain Res. 2006 Jun 3;170(1):110-8. doi: 10.1016/j.bbr.2006.02.009. Epub 2006 Mar 31.
The opiate withdrawal syndrome powerfully motivates opiate seeking and abuse. Development of effective medications for opiate withdrawal symptoms is thus a primary research goal and heavily relies on improved experimental models. This study was carried out to establish a clinically relevant paradigm to assess somatic opiate withdrawal in mice. Female and male C57BL/6J mice were treated with saline or increasing morphine doses (10-50mg/kg or 20-100mg/kg) during 6 consecutive days and tested for the spontaneous expression of somatic opiate withdrawal signs 8, 32, 56 and 80 h after last drug administration. Contrary to opioid receptor antagonist-precipitated procedures, the spontaneous opiate withdrawal paradigm used here revealed interesting gender- and morphine dose-linked differences. In particular, 56 h after last morphine administration elevated global opiate withdrawal scores were still evident in female but not in male mice treated with 20-100mg/kg. The severity of somatic opiate withdrawal directly correlated with the prior cumulative morphine exposure. Timing of expression of somatic opiate withdrawal signs also varied as a function of both gender and morphine dose. For example, expression of paw tremors and wet dog shakes was earlier in opiate-withdrawn male than in female mice. Overall, these findings highlight the possibility to detect gender- and opiate dose-linked differences in the expression and duration of somatic opiate withdrawal using a clinically relevant research model. The behavioral paradigm described here may represent a more appropriate tool to investigate the neurobiological bases of opiate withdrawal as opposed to opioid receptor antagonist-precipitated opiate withdrawal procedures.
阿片类药物戒断综合征强烈地促使人们寻求和滥用阿片类药物。因此,开发治疗阿片类药物戒断症状的有效药物是一项主要的研究目标,并且在很大程度上依赖于改进的实验模型。本研究旨在建立一种与临床相关的范式,以评估小鼠的躯体阿片类药物戒断情况。对雌性和雄性C57BL/6J小鼠连续6天给予生理盐水或递增剂量的吗啡(10 - 50mg/kg或20 - 100mg/kg),并在最后一次给药后8、32、56和80小时测试躯体阿片类药物戒断体征的自发表达情况。与阿片受体拮抗剂诱发的程序不同,此处使用的自发阿片类药物戒断范式揭示了有趣的性别和吗啡剂量相关差异。特别是,在最后一次给予吗啡56小时后,接受20 - 100mg/kg治疗的雌性小鼠中仍有明显升高的总体阿片类药物戒断评分,而雄性小鼠中则没有。躯体阿片类药物戒断的严重程度与先前累积的吗啡暴露直接相关。躯体阿片类药物戒断体征的表达时间也因性别和吗啡剂量而异。例如,阿片类药物戒断的雄性小鼠爪子震颤和湿狗样抖动的表达比雌性小鼠更早。总体而言,这些发现凸显了使用与临床相关的研究模型检测躯体阿片类药物戒断表达和持续时间中性别和阿片剂量相关差异的可能性。与阿片受体拮抗剂诱发的阿片类药物戒断程序相比,此处描述的行为范式可能是研究阿片类药物戒断神经生物学基础的更合适工具。